Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 24.375p 23.75p 25.00p 24.375p 24.375p 24.375p 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.4 -0.2 0.0 721.0 14.68

Venn Life Share Discussion Threads

Showing 1001 to 1018 of 1025 messages
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
DateSubjectAuthorDiscuss
06/12/2016
15:46
Strangely enough hangman, I can't be bothered to tell you.....
eburne1960
06/12/2016
09:32
B1ggles. I noticed that too. And perhaps more oddly the article didn't seem to result in a single buy either. It's not a bad thing being under the radar but publicly we seem to be bordering on the non-existent at present.
investordave
06/12/2016
08:41
Hi this may seem a silly question, will shareholders be getting shares inIntegumen, or will VENN be getting them to hold ? Have been away for a while, & can't be bothered to read through all the RNS's
mr hangman
05/12/2016
23:17
I think Venn is unknown, rather than unloved. There's no news to buy into yet. These smaller companies can take ages to get both business traction and investment traction. Given the track record of the CEO, I'm sure there will be a point when the expansion efforts crystallize into clean profits to show obvious shareholder value, otherwise there would be no point in building it as he has been doing. Its not being built by a medical enthusiast with an interest in the products as far as I can see - its being built as a business opportunity by people who know about the market.
yump
05/12/2016
21:25
Appears to be more focus on the share trades rather than the IPO of Integumen! Here's a short update. The holding company Integumen now contains the following assets:- * Labskin – Living human skin equivalent model for pharmaceutical and cosmetic testing (on market) * Clarogel – Novel OTC anti-acne/blemish control product (late stage development). * A disposable oral hygiene product targeted at the professional market. Already selling well in Germany...although I'm unaware if the acquisition of this company has completed yet. * Visible Youth – A premium skin care range with a unique blend of active ingredients supported by scientific evidence. Due to launch H2 2017. * Wound pHase – a chronic wound diagnostic tool based upon a novel pH sensitive hydrogel It is intimated that these collective assets have received c.£15m investment spend up until now, with oral hygiene product already selling in relatively high volume with plans to extend in a number of markets. Will be interesting to learn how much Integumen plan to raise at IPO. Kind regards, GHF
glasshalfull
05/12/2016
18:21
Just seen my above post. There, there. I think I will stick to only using computer in future.
cocker
05/12/2016
14:33
Venn appears to be very unloved at the moment. The lack of investment interest in the Company is v surprising.
investordave
05/12/2016
14:32
Yep fraid so. And the small sales are continuing I see.
investordave
25/11/2016
09:12
I could not have put it better myself LBO. All to often I see companies acquisition's used as a scapegoat for poor management or company failings. The constant amount of Directors running these AIM listed companies for their own end, is far more common these days then when it was back say some ten years ago. It happens because they are almost immune from prosecution & therefore its a free for all. Finding the gem in amongst a pile of rocks gets harder by the day.
cocker
25/11/2016
08:42
You can invest in a below average business with a great management and make a fortune or invest in great business with a below average management team and loose a fortune!!!! And remember the AIM casino as we all know too well has many great business ideas and business plans in which no shareholder value is ever created but rather only destroyed. The lack of regulation allows poor management to continually line their own pockets at shareholders expense.
lbo
22/11/2016
17:33
Apart from understanding the business, the point that LBO makes is relevant I think, in that its worth trying to make sure that you understand the motives of the BOD, regardless of what they say about shareholder value. Then its perhaps possible to align your own strategy to match what you think their's might be and get out at an appropriate time. ie. there's a big difference between the motives of a BOD who are founders, who have worked from scratch to grow a business organically and then bring it to market to make something even bigger, compared to a group of multiple-company directors and ex-fund managers who float something with an acquisition strategy, compared to another group of media guys who claim they are going to change the world with some new fangled thing.
yump
22/11/2016
11:20
I see someone has just sold £50 of shares. It has always struck me as bizarre when people do this. Why bother for such a low amount?
investordave
21/11/2016
16:02
LBO - So don't invest if you don't trust the company. It's quite simple really.
investordave
21/11/2016
14:33
The same thing was said about Alltracel yet investors were fleeced. Looking at the Warrants, options and salaries again not much has changed
lbo
19/11/2016
12:18
Investing is a constant risk v return balancing act. AIM is very risky but it hasn't changed much in recent years- good and bad. You especially can't afford to be impatient with your AIM stocks. My portfolio at the moment is 80% AIM and at the moment I'm well up in 10 and well down in 2 and a bit down (7%) in VENN. I never buy on a whim. If I like the look of a stock I place it on my watch list for a while before investing. Although down at the moment I believe VENN is a winner, good honest management in a dream sector with a growing reputation and client list.
chadders
18/11/2016
08:48
rivaldo - and yet still no buyers.. V odd. I'm going to add at the end of the month when funds available.
investordave
18/11/2016
08:29
Great to see the sale of Innovenn proceeding smoothly and now completed. The IPO process takes some time - perhaps 2-3 months for a small cap like Integumen - so hopefully it may happen before Xmas, otherwise I can see it floating in early January. I expect the share price to move up nicely from here. With 2.39p EPS forecast this year, and 2.68p EPS next year, we now have a core business on almost a single-figure P/E, with cash in the bank, and a sizeable stake in a company about to IPO for a few more £m's.
rivaldo
18/11/2016
07:50
Very vague statement as usual. It's like Alltracel all over again when shareholders suffered massive losses from when it IPO to eventually being sold for a fraction of that while others walked away with salaries and exercised cheap share options.
lbo
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20161207 22:15:44